Pacira BioSciences, Inc. (PCRX) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Total Cash From Operating Activities Chart for Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX) operating cash flow for FY2025 was USD 152.0M, a -19.7% change from FY2024. Pacira BioSciences, Inc.'s operating cash flow moved from USD -29.2M in 2008 to USD 152.0M in 2025 over 17 years. Operating cash flow compound annual growth rate: 5-year CAGR of 14.6%, 10-year CAGR of 18.0%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.45B
- Implied Share Price
- $36.34
- Enterprise Value
- $1.14B
- Revenue (TTM)
- $746.16M
- EBITDA
- $123.97M
- Profit Margin
- 1.96%
- Trailing P/E
- 103.83
- Forward P/E
- 6.25
- Price/Book (MRQ)
- 1.46
- Price/Sales (TTM)
- 1.94
- EV/EBITDA
- 9.84
- EV/Revenue
- 1.53
- Dividend Yield
- —
- Book Value
- $16.87
- Free Cash Flow (FY2025)
- $136.66M
- Free Cash Flow Yield
- 9.42%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.